Orthofix Medical Inc

Orthofix Medical Inc(OFIX)股票分析

$9.590

+0.353 (+3.68%)收盘时

Loading chart…
最高
9.724
开盘
9.420
成交量加权均价
9.55
成交量
317.97K
市值
505.89M
最低
9.350
成交额
3.04M
企业价值/息税折旧摊销前利润(TTM)
4.99

Orthofix Medical Inc. is a global medical technology company. It offers a comprehensive portfolio of spinal hardware, bone growth therapies, limb reconstruction solutions, biologics and enabling technologies, including the 7D FLASH Navigation System. Its Global Spine segment offers two primary product categories: bone growth therapies and spinal implants, biologics, and enabling technologies. It provides implantable medical devices, biologics, enabling technologies, and other regenerative solutions which aim to restore the quality of life of patients suffering from diseases and traumas of the spine. It offers a variety of treatment solutions that incorporate multiple treatment modalities, such as mechanical, biological, and electromagnetic modes. Its Global Limb Reconstruction segment offers products and solutions for the underserved limb reconstruction market that encompasses four pillars: deformity correction, limb lengthening, complex fracture management, and limb preservation.

AI 分析 of Orthofix Medical Inc (OFIX)

持有

Orthofix Medical Inc is currently priced at $9.17, which is significantly below the average analyst price target of $13. However, the stock has a negative RSI of 46.37, indicating a potential lack of momentum. The company has also reported a 38.21% year-to-date decline, raising concerns about its long-term viability. While there are positive signs such as a recent revenue beat and an increase in adjusted EBITDA guidance, the ongoing investigation into fiduciary breaches poses a significant risk. Therefore, it may be prudent to hold off on buying until there is more clarity on these issues.

分析师评级(7)

上行空间 +122.42%
买入
6 买入
1 持有
0 卖出
当前: 9.59
最低
18.00
平均
21.33
最高
24.00

Canaccord

2026-08-10

目标价

$13

买入

Barrington

2026-08-06

目标价

$14

跑赢大盘

Stifel

2026-08-05

目标价

$13

买入

Stifel

2026-03-09

目标价

$18

买入

Canaccord

2026-02-26

目标价

$20

买入

估值指标

Orthofix Medical Inc(OFIX)当前预期市盈率为 500.00,5 年平均预期市盈率为 19.92。

预期市盈率

严重高估
5 年均值 P/E
19.92
当前P/E
500.00
高估
190.96
低估
-151.12

预期 EV/EBITDA

低估
5 年均值 EV/EBITDA
8.94
当前EV/EBITDA
4.99
高估
11.73
低估
6.14

预期市销率

低估
5 年均值 P/S
0.78
当前P/S
0.43
高估
1.04
低估
0.51

Alphio AI 对 OFIX 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%OFIX

$10.69

情景价格

基

基准

基准 · 50%OFIX

$10.56

情景价格

悲

悲观

悲观 · 25%OFIX

$10.47

情景价格

持有 OFIX 的大户

A

Armistice Capital LLC

+ 持有OFIX

-6.13%

3个月收益率

事件时间线

2026-08-05 (ET)

07:30:00

Orthofix Reports Q2 Revenue of $210.9M, Beating Expectations

07:30:00

Orthofix Raises 2026 Net Sales Guidance to $845-$855 Million

2026-07-06 (ET)

09:00:00

Nasdaq and S&P 500 Futures Rise as Chip Stocks Rebound

08:00:00

Orthofix Expects Medicare Reimbursement to Return to Pre-2026 Levels

2026-05-21 (ET)

10:00:00

Orthofix Cuts FY Revenue Guidance, Shares Down 19.6% to $9.77

资讯

OFIX 常见问题 —— 由 Alphio AI 解答

Orthofix Medical Inc. is a global medical technology company. It offers a comprehensive portfolio of spinal hardware, bone growth therapies, limb reconstruction solutions, biologics and enabling technologies, including the 7D FLASH Navigation System. Its Global Spine segment offers two primary product categories: bone growth therapies and spinal implants, biologics, and enabling technologies. It provides implantable medical devices, biologics, enabling technologies, and other regenerative solutions which aim to restore the quality of life of patients suffering from diseases and traumas of the spine. It offers a variety of treatment solutions that incorporate multiple treatment modalities, such as mechanical, biological, and electromagnetic modes. Its Global Limb Reconstruction segment offers products and solutions for the underserved limb reconstruction market that encompasses four pillars: deformity correction, limb lengthening, complex fracture management, and limb preservation. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Orthofix Medical Inc is currently priced at $9.17, which is significantly below the average analyst price target of $13. However, the stock has a negative RSI of 46.37, indicating a potential lack of momentum. The company has also reported a 38.21% year-to-date decline, raising concerns about its long-term viability. While there are positive signs such as a recent revenue beat and an increase in adjusted EBITDA guidance, the ongoing investigation into fiduciary breaches poses a significant risk. Therefore, it may be prudent to hold off on buying until there is more clarity on these issues.

7 analysts cover OFIX: 6 rate it Buy, 1 Hold and 0 Sell. The average price target is 21.33.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易